补肾健脾法治疗肝肾综合征临床研究
|
摘要
目的探讨应用补肾健脾方治疗肝肾综合征的临床疗效.方法将84例肝硬化合并肝肾综合征患者随机分成两组,治疗组42例采用补肾健脾法进行治疗,对照组42例为西医综合治疗,观察两组肝肾功能情况,即总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、γ谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)、24 h尿量、尿素氮(BUN)和血肌酐(Cre)的变化.结果治疗组治疗后总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、γ谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)均得到显著改善(P<0. 05);对照组均无显著改善(P>0. 05).治疗组与对照组比较,TBIL,ALT,AST及ALP均得到显著改善(P<0. 05),但两组GGT差异不显著(P>0. 05).治疗组患者治疗前后24 h尿量、BUN和Cre均得到显著改善(P<0. 05),对照组治疗前后24 h尿量、BUN和Cre均无显著差异(P>0. 05);治疗组与对照组比较24 h对照组尿量、BUN和Cre均得到显著改善(P<0. 05).结论补肾健脾法对肝肾综合征的治疗具有较好疗效.
Objective To explore clinical effect of hepatorenal syndrome treated with methods of reinforcing kidney and strengthening spleen. Method 84 cases of liver cirrhosis with hepatorenal syndrome were randomly divided into two groups,42 patients with reinforcing kidney and strengthening spleen in experimental group,42 patients with Western medicine treatment in control group,were observed the changes of liver and kidney function,total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST),γ-glutamyl(GGT),alkaline phosphatase(ALP),24 h urine volume,BUN and Cre. Results After treatment,the treatment group was better than that of control group in TBIL,ALT,AST,ALP,24 h urine volume,BUN and Cre(P<0. 05),but GGT in the control group showed no significant improvement(P>0. 05). Conclusion We have satisfied the effects on hepatorenal syndrome with the method of reinforcing kidney and strengthening spleen.
Objective To explore clinical effect of hepatorenal syndrome treated with methods of reinforcing kidney and strengthening spleen. Method 84 cases of liver cirrhosis with hepatorenal syndrome were randomly divided into two groups,42 patients with reinforcing kidney and strengthening spleen in experimental group,42 patients with Western medicine treatment in control group,were observed the changes of liver and kidney function,total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST),γ-glutamyl(GGT),alkaline phosphatase(ALP),24 h urine volume,BUN and Cre. Results After treatment,the treatment group was better than that of control group in TBIL,ALT,AST,ALP,24 h urine volume,BUN and Cre(P<0. 05),but GGT in the control group showed no significant improvement(P>0. 05). Conclusion We have satisfied the effects on hepatorenal syndrome with the method of reinforcing kidney and strengthening spleen.
引文
[1]彭阿平,朱萱.肝肾综合征的发病机制及诊治的研究进展[J].世界华人消化杂志,2015,23(9):1440-1446.
[2] A rroyo V,Genes P,Gerber A L,et al. Definition and diagonalstic criteria of refractory ascites and hepatorenal syndrome in cirrhoses[J]. Herpetology,1996,25(1):164-176.
[3] Bittencourt P L,Farias A Q,Terra C. Renal failure in cirrhosis:Emerging concepts[J]. World J Hepatol,2015,7(21):2336-2343.
[4] Piano S,Rosi S,Maresio G,et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites[J]. J Hepatol,2013,59(3):482-489.
[5]宋日新,姜国红,孔莉娟,等.中西医结合治疗肝肾综合征临床观察[J].齐齐哈尔医学院学报,2008,30(6):565-566.
[6]肖倩,张旸,谭善忠.温肾利水法联合前列地尔治疗肝硬化并发肝肾综合征29例[J].临床肝胆病杂志,2012,28(3):189-191.
[7]孙媛媛,赵玉洁,赵金畅,等.人参皂苷抗肝纤维化作用机制研究进展[J].中草药,2017,48(9):1912-1915.
[8]刘鸣昊,薛博瑜.近5年来肝纤维化中医证治用药规律的文献研究[J].中国实验方剂学杂志,2011,17(18):279-280.
[9]吴疆,魏巍,袁永兵.补骨脂的化学成分和药理作用研究进展[J].药物评价研究,2011,34(3):217-219.
[10]甘草酸制剂肝病临床应用专家委员会.甘草酸制剂肝病临床应用专家共识[J].临床肝胆病杂志,2016,32(5):844-848.
[2] A rroyo V,Genes P,Gerber A L,et al. Definition and diagonalstic criteria of refractory ascites and hepatorenal syndrome in cirrhoses[J]. Herpetology,1996,25(1):164-176.
[3] Bittencourt P L,Farias A Q,Terra C. Renal failure in cirrhosis:Emerging concepts[J]. World J Hepatol,2015,7(21):2336-2343.
[4] Piano S,Rosi S,Maresio G,et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites[J]. J Hepatol,2013,59(3):482-489.
[5]宋日新,姜国红,孔莉娟,等.中西医结合治疗肝肾综合征临床观察[J].齐齐哈尔医学院学报,2008,30(6):565-566.
[6]肖倩,张旸,谭善忠.温肾利水法联合前列地尔治疗肝硬化并发肝肾综合征29例[J].临床肝胆病杂志,2012,28(3):189-191.
[7]孙媛媛,赵玉洁,赵金畅,等.人参皂苷抗肝纤维化作用机制研究进展[J].中草药,2017,48(9):1912-1915.
[8]刘鸣昊,薛博瑜.近5年来肝纤维化中医证治用药规律的文献研究[J].中国实验方剂学杂志,2011,17(18):279-280.
[9]吴疆,魏巍,袁永兵.补骨脂的化学成分和药理作用研究进展[J].药物评价研究,2011,34(3):217-219.
[10]甘草酸制剂肝病临床应用专家委员会.甘草酸制剂肝病临床应用专家共识[J].临床肝胆病杂志,2016,32(5):844-848.